Document Detail


Current state of thrombolytic therapy.
MedLine Citation:
PMID:  10980844     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
More than 200,000 people have been enrolled into clinical trials examining different reperfusion strategies for patients with acute myocardial infarction. Each year approximately 1 million people in the United States experience acute myocardial infarction. Thrombolytic agents, including streptokinase and tissue-type plasminogen activator, activate plasminogen. These agents are often divided into "fibrin-specific" and "non-fibrin-specific" drugs. New thrombolytic agents designed to address several of the shortcomings of existing thrombolytics are in various stages of clinical development.
Authors:
D A Vorchheimer
Related Documents :
9692644 - Timi grade flow, mortality, and the gusto-iii trial.
2807704 - Therapy for myocardial infarction: effect on trends in coronary disease mortality.
9585864 - Guidelines to reducing delays in administration of thrombolytic therapy in acute myocar...
10580214 - A community hospital's effort to expedite treatment for patients with chest pain.
128794 - Cardiomyopathy in the dog.
9692644 - Timi grade flow, mortality, and the gusto-iii trial.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Current cardiology reports     Volume:  1     ISSN:  1523-3782     ISO Abbreviation:  Curr Cardiol Rep     Publication Date:  1999 Sep 
Date Detail:
Created Date:  2000-12-20     Completed Date:  2000-12-20     Revised Date:  2008-11-21    
Medline Journal Info:
Nlm Unique ID:  100888969     Medline TA:  Curr Cardiol Rep     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  212-20     Citation Subset:  IM    
Affiliation:
Mt. Sinai Medical Center, Zena and Michael A. Wiener Cardiovascular Institute, 1 Gustave L. Levy Place, Box 1030, New York, NY 10029-6574, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Fibrinolytic Agents / therapeutic use*
Humans
Myocardial Infarction / drug therapy*,  epidemiology
Myocardial Reperfusion
Plasminogen Activators / therapeutic use
Randomized Controlled Trials as Topic
Recombinant Proteins / therapeutic use
Streptokinase / therapeutic use
Survival Analysis
Thrombolytic Therapy* / methods
Tissue Plasminogen Activator / therapeutic use
Urokinase-Type Plasminogen Activator / therapeutic use
Chemical
Reg. No./Substance:
0/Fibrinolytic Agents; 0/Recombinant Proteins; 133652-38-7/reteplase; 153484-31-2/SUN 9216; 99149-95-8/saruplase; EC 3.4.-/Streptokinase; EC 3.4.21.-/Plasminogen Activators; EC 3.4.21.68/Tissue Plasminogen Activator; EC 3.4.21.73/Urokinase-Type Plasminogen Activator

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Low molecular weight heparin in acute coronary syndromes.
Next Document:  Non-lipid-lowering effects of statins on atherosclerosis.